Cellivery Registers Patent for TSDT Platform Technology... Full-Scale Entry into Chinese Bio-Pharmaceutical Market

"Establishing a Business and Technical Bridgehead for Expansion into China"

[Asia Economy Reporter Minwoo Lee] Cellivery has received a patent from Chinese authorities for its pharmacological substance in vivo delivery technology (TSDT) platform through intercellular continuous transfer. The company is set to make a full-scale entry into the Chinese bio and pharmaceutical market.

On the 24th, Cellivery announced that it received a patent registration decision notice from the China National Intellectual Property Administration (CNIPA) for the TSDT platform patent.

This patent is a foundational technology for delivering pharmacological substances into cells in vivo for disease treatment by developing a hydrophobic cell membrane-permeable peptide (aMTD) sequence that effectively delivers biologically active molecules into the cytoplasmic membrane surrounding cells. Currently, negotiations are underway with multiple overseas pharmaceutical companies regarding the development of therapies combining this patented technology with gene therapy and nucleic acid therapies such as short interfering RNA (siRNA) and antisense oligonucleotides (ASO).

With this, Cellivery's TSDT platform technology is now protected by intellectual property rights in China, following the United States, Europe, Japan, Canada, Korea, and Australia. A representative from Cellivery's Business Development Headquarters stated, "This patent registration decision in China, the second-largest pharmaceutical market as a single country, secures a technological and business foothold for market entry. It is not only a crucial factor that can enhance the value of the TSDT platform technology in licensing negotiations with overseas pharmaceutical companies but also lays the foundation to solidify the possibility of joint new drug development and TSDT platform technology transfer targeting Chinese bio and pharmaceutical companies."